查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2072303

化膿性汗腺炎（HS）：新型療法、未滿足的需求和TPP洞察報告，2026年

Hidradenitis Suppurativa (HS) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國HS市場預計將從2025年的2.05億美元成長到2035年的6.2億美元。
  • 以下因素正在推動市場成長：
  • 針對主要發炎路徑生物製藥的廣泛應用
  • 提高對中重度化膿性汗腺炎病例的疾病認知和診斷準確率。
  • 未來的成長取決於能否成功開發出能夠持續控制疾病並改善患者長期療效的新型標靶治療。

化膿性汗腺炎 (HS) 的新療法及對 TPP 的深入研究

Thelansis 的《化膿性汗腺炎 (HS)：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026》對該適應症的關鍵新興療法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。

化膿性汗腺炎（HS）概述

化膿性汗腺炎（HS）是一種慢性全身性發炎性毛囊疾病，其特徵是反覆疼痛的深部結節、膿瘍、化膿性瘻管和進行性性疤痕形成。雖然病灶在解剖學上表現為皮膚上易磨損且富含頂泌汗腺的區域，但其主要病理生理機制源於毛囊頂端漏斗部的角化過度和阻塞，隨後發生毛囊破裂、免疫調節和繼發性微生物增殖。診斷主要依靠臨床表現，治療策略則根據Hurley分期系統制定，並監測代謝合併症。到2026年，治療策略正迅速從急性期的生活方式介入和經驗性抗生素抑制療法轉向針對中重度疾病的特異性生物療法。雖然 TNF-α 抑制劑仍是一種基本治療方法，但先進的白細胞介素-17A 和白細胞介素-17A/F 抑制劑已在分子水平上廣泛用於抑制持續性皮膚清除和發炎隧道形成，通常與廣泛的手術切除或去除解剖固定的纖維化病變的頂蓋相結合。

主要亮點

  • 在法國，預計到 2025 年，膿皰瘡 (HS) 的診斷病例數將增加到 2035 年的 178,286 例。
  • 化膿性汗腺炎是一種慢性復發性發炎性皮膚病，其特徵是疼痛性病灶、膿瘍形成和進行性疤痕形成。
  • 這種疾病帶給患者巨大的生理和心理負擔，嚴重影響他們的生活品質。
  • 診斷延誤和長期治療選擇有限，導致疾病活動持續存在，患者需求無法滿足。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興療法條件的患者
  • 大公司
  • 主要作用機制
  • 發布日期預測等。
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要療法的有效性
  • 未滿足需求的關鍵領域
  • 主要未滿足需求的市場規模估算
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵意見領袖對領先新興療法的見解
  • 意識
  • 預期用途/處理線
  • 主要未滿足需求得到滿足的程度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Avalo Therapeutics, Inc.
  • ACELYRIN Inc.
  • Incyte Corporation
  • Novartis Pharmaceuticals
  • UCB Biopharma SRL
  • Aclaris Therapeutics, Inc.
  • Takeda
  • Sanofi
  • Merck Sharp &Dohme LLC
  • Sonoma Biotherapeutics, Inc.
  • Almirall, SA
  • Shanghai Huaota Biopharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • AbbVie
  • Insmed Incorporated
  • Pfizer
  • Boehringer Ingelheim
  • MoonLake Immunotherapeutics AG
  • Vanda Pharmaceuticals
  • Janssen Research &Development, LLC
  • Bluefin Biomedicine, Inc.
  • Navigator Medicines, Inc.
  • Sinocelltech Ltd.
  • Leadingtac Pharmaceutical（Shaoxing）Co., Ltd.
  • Zura Bio Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要療法概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：初步調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興療法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興療法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Hidradenitis Suppurativa (HS) Emerging Therapy and TPP Insights

Thelansis's "Hidradenitis Suppurativa (HS) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Hidradenitis Suppurativa (HS) Overview

Hidradenitis suppurativa is a chronic, systemic inflammatory follicular disorder characterized by recurrent, painful deep-seated nodules, abscesses, draining sinus tracts, and progressive scarring. Although lesions manifest anatomically in intertriginous zones rich in apocrine glands, the primary pathobiology is rooted in hyperkeratosis and occlusion of the terminal hair follicle infundibulum followed by follicular rupture, immune dysregulation, and secondary microbial propagation. Diagnosis is clinical, utilizing the Hurley staging system to direct intervention and tracking metabolic comorbidities. Management in 2026 transitions rapidly from acute lifestyle and empiric antibiotic suppression to target-specific biological therapies for moderate-to-severe disease. While TNF-alpha inhibition remains foundational, molecular strategies widely utilize advanced interleukin-17A and interleukin-17A/F inhibitors to achieve sustained skin clearance and reduce inflammatory tunnel formation, complemented by wide surgical excision or deroofing procedures for anatomically fixed fibrotic disease structures.

Key Highlights

  • In France, diagnosed Hidradenitis Suppurativa (HS) cases are projected to increase from 138,486 in 2025 to 178,286 by 2035.
  • HS is a chronic, recurrent inflammatory skin disease associated with painful lesions, abscess formation, and progressive scarring.
  • The disease imposes a substantial physical and psychosocial burden, significantly affecting patients' quality of life.
  • Delayed diagnosis and limited long-term treatment options continue to contribute to persistent disease activity and unmet patient needs.

Market Overview

  • The France HS market is projected to grow from $205M in 2025 to $620M by 2035.
  • Market growth is driven by:
  • Increasing adoption of biologic therapies targeting key inflammatory pathways
  • Growing disease awareness and improved diagnosis of moderate-to-severe HS cases
  • Future growth will depend on the successful development of novel targeted therapies capable of achieving sustained disease control and improving long-term patient outcomes.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Avalo Therapeutics, Inc.
  • ACELYRIN Inc.
  • Incyte Corporation
  • Novartis Pharmaceuticals
  • UCB Biopharma SRL
  • Aclaris Therapeutics, Inc.
  • Takeda
  • Sanofi
  • Merck Sharp & Dohme LLC
  • Sonoma Biotherapeutics, Inc.
  • Almirall, S.A.
  • Shanghai Huaota Biopharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • AbbVie
  • Insmed Incorporated
  • Pfizer
  • Boehringer Ingelheim
  • MoonLake Immunotherapeutics AG
  • Vanda Pharmaceuticals
  • Janssen Research & Development, LLC
  • Bluefin Biomedicine, Inc.
  • Navigator Medicines, Inc.
  • Sinocelltech Ltd.
  • Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
  • Zura Bio Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)